Jasper Therapeutics, Inc. (JSPR) Form S-3 — Oct 14, 2026
Jasper Therapeutics filed an S-3 shelf registration registering the resale of up to 284,013,011 shares of common stock issuable upon conversion of 4,655,951 shares of PIPE preferred stock sold for approximately $132.0 million in connection with its July 16, 2026 acquisition of Kira Pharmaceuticals. The company will receive no proceeds from these sales, and the resale share count dwarfs the 33,274,561 shares currently outstanding. Conversion of the preferred stock still requires stockholder approval, and if Jasper fails to deliver shares after the earlier of that approval or twelve months from issuance, preferred holders can demand cash equal to fair value of undelivered shares.
Key figures
- Gross Proceeds
- 132000000
- Offering Price
- 0.4956
- Shares Offered
- 284013011
- Shares Outstanding
- 33274561
- Cvr payment usd
- 30000000
- Mirador upfront usd
- 12000000
- Reverse split range
- 1-for-15 to 1-for-35
- Pipe gross proceeds usd
- 132000000
- Mirador sales milestones usd
- 350000000
- Accumulated deficit usd june 2026
- 320600000
- Conversion ratio preferred to common
- 61
- Kira shareholders post financing percent
- 49.86%
- Financing investors post financing percent
- 43.46%
- Resale shares issuable from pipe preferred
- 4655951
- Potential fully converted shares outstanding
- 616153351
- Mirador development regulatory milestones usd
- 108500000
- Pre transaction stockholders post financing percent
- 6.68%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.